median OI of x in the first day of life, iNO improved OI in all cases, although there was no significant effect on BPD, IVH or mortality. Our data supports the findings of earlier studies that iNO can improve respiratory function in PPHN associated with PPROM. Further prospective trials are needed to assess long term outcomes in this subsection of babies with severe respiratory failure following perinatal delivery.

**G131(P)**

MICROBIOLOGICAL FLORA AND THEIR SENSITIVITIES TO ANTIBIOTICS, IN A TERTIARY NEONATAL UNIT AT NORTH EAST OF ENGLAND

1H Dumelow, 2M Narayanan, 1N Athiraman. 1Neonates, Newcastle Hospitals NHS Foundation Trust, Newcastle-Upon-Tyne, UK; 2Microbiology, Newcastle Hospitals NHS Foundation Trust, Newcastle-Upon-Tyne, UK

10.1136/archdischild-2015-308599.129

Background Sepsis remains one of the biggest causes of neonatal morbidity and mortality. The antibiotic guidelines used on our NICU are influenced heavily by national epidemiological data from NeonIN, collected from 2006–2008. The objective of this service improvement project was to establish the current epidemiology of bacteremia-causing pathogens on our unit, and their sensitivity to our empirical antibiotic regimens, in order to establish whether our guidelines remain adequate.

Methods Laboratory data on positive blood cultures from April 2011 to March 2014 were analysed. We established the common pathogens, their incidence, and their sensitivity to recommended empirical antibiotics.

Results Out of 2367 blood cultures analysed, 116 (5%) were positive for an organism. These were made up of 70 (60%) Coagulase Negative Staphylococcus, 13 (11%) Group B Streptococcus, 12 (10%) coliforms, 8 (7%) Enterococcus faecalis and 6 (5%) Staphylococcus aureus. The remaining were rarer Gram positive organisms and 1 Haemophilus influenzae. 100% of organisms that commonly cause early-onset sepsis (GBS and Escherichia coli n = 19) were sensitive to the recommended antibiotic combination of penicillin and gentamicin. 100% of non-CoNS pathogens were sensitive to the Amoxicillin and/or Gentamicin in the late onset sepsis regimen of Amoxicillin/Fluclacoxillin/Gentamycin. Sensitivity to Fluclacoxillin was measured at 22% of positive cultures tested. Only 54% of CoNS was tested for sensitivity to Vancomycin, which is the recommended antibiotic for suspected CoNS (eg. central line in situ). 100% of these were sensitive.

Conclusions Initial analysis shows that guidelines are appropriate for early-onset sepsis and non-CoNS late-onset sepsis. However, the data questions the need for Fluclacoxillin in the LOS regimen. There is apparent inconsistency in testing of CoNS for sensitivity to Vancomycin, not allowing a full judgement as to whether this provides adequate cover. The need for Ceftazidime (recommended with Vancomycin when a baby remains sick despite the Amoxicillin/Fluclacoxillin/Gentamycin regimen) is questioned by this study.

**G132(P)**

IMPACT OF IMPLEMENTING NATIONAL GUIDELINES ON ‘ANTIBIOTICS FOR EARLY-ONSET NEONATAL INFECTION’ ON A LEVEL 2 NEONATAL UNIT

E Liew, A Moylan, T Wickham. Starlight Neonatal Unit, Barnet Hospital, Royal Free London NHS Foundation Trust, London, UK

10.1136/archdischild-2015-308599.130

Aims NICE projected cost savings of £50 million per annum with its guideline on ‘Antibiotics for early-onset neonatal infection’. We assessed the impact of implementing this guideline in a Level 2 Neonatal Unit.

Method Retrospective case notes review of neonates born in our hospital who received antibiotics within 72 h of birth. We compared a pre-guideline implementation cohort (March–April 2012) and a post-guideline cohort (March–April 2013). Data on characteristics of the neonates, reasons for starting antibiotics, length of antibiotics course and adherence to the guidelines were collected.

Results 138 neonates were identified, 57 in the pre-guideline cohort and 81 in the post-guideline cohort (Figure 1). From the pre-guideline cohort, 39 were included. From the post-guideline cohort, 59 were included. The cohorts were matched. Overall, post-guideline implementation, there is a 51% increase in the number of neonates receiving antibiotics, with the main reason being for neonatal signs and symptoms in both cohorts (72% and 77%) (Figure 2). However, there was a 9% rise in neonates being started on antibiotics because of maternal risk factors alone in the post guideline cohort. This is due to the increasing number of mothers started on intravenous antibiotics for suspected invasive bacterial infection, although the criteria defining ‘suspected invasive bacterial infection’ are unclear. Post-guideline implementation, the number of neonates receiving more than...